 |
HOME | CONTACT |
|
|
|
Nektar also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
* LEVADEX™ is a trademark and TEMPO® is a registered trademark of MAP Pharmaceuticals; Cimzia® is a registered trademark of UCB and OMONTYS is a registered trademark of Affymax, Inc.
BAX 855 (pegylated rFVIII molecule)
Longer-acting therapeutic clotting proteins
Nektar and Baxter have multiple partnerships in hemophilia. Under the terms of these collaborations, Nektar is entitled to receive royalties on the global sales of long-acting clotting protein programs for hemophilia that use Nektar's PEGylation and advanced polymer conjugate technologies. Nektar is also entitled to contract research and manufacturing revenues for these programs. Nektar's innovative releasable linker conjugate technology is used in the development of these therapeutics.
LEVADEX™
Under the terms of a license agreement between Nektar and MAP Pharmaceuticals, Nektar is entitled to receive royalties on the global sales of LEVADEX™ for all indications. LEVADEX is an orally inhaled version of dihydroergotamine (DHE), self-administered via MAP's proprietary TEMPO® inhaler. DHE is available as an intravenous therapy which has been used in clinical settings for over 50 years to safely treat migraine. A New Drug Application (NDA) for LEVADEX is currently being reviewed by the U.S. Food and Drug Administration (FDA) and the PDUFA is March 26, 2012.
Cipro Inhale
Under development by Bayer Healthcare, inhaled cipro is a targeted inhaled antibiotic therapy for pulmonary infections in cystic fibrosis patients. It is a specially formulated form of ciprofloxacin betaine that is delivered via dry powder inhalation to the target area of the lung. The investigational product candidate is currently in Phase 2 clinical trials in patients and features a small, hand-held inhaler for ease-of-use. Nektar is entitled to royalties on sales of Cipro Inhale upon commercialization.
NKTR-061
Amikacin Inhale combines a novel, preservative-free liquid formulation of antibiotic amikacin with a Liquid Pulmonary Technology (LPT™) originally developed by Nektar. The product is under development to treat Gram-negative pneumonias. 
Naloxegol (NKTR-118)
Oral Naloxegol (NKTR-118) is a novel peripheral opioid antagonist created using Nektar's advanced polymer conjugate technology.
Naloxegol and opioid co-formulation product
Oral NKTR-119 is an investigational drug candidate that is a co-formulation of Oral Naloxegol (NKTR-118) and an opioid analgesic. The product is in preclinical stages for the treatment of pain without the gastrointestinal side effects associated with traditional opioid therapies.
NKTR-181
NKTR-181 is a new oral opioid analgesic candidate in development for the treatment of chronic pain. It is designed to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies. NKTR-181 is a novel mu-opioid agonist created using Nektar's proprietary polymer conjugate technology and its differentiating properties are inherent to the design of its new molecular structure.
NKTR-171
NKTR-171 is a drug candidate designed to treat neuropathic pain without the CNS side effects. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
NKTR-192
NKTR-192 is Nektar Therapeutics' product candidate for the treatment of moderate to severe acute pain. NKTR-192 is a novel mu-opioid analgesic created using Nektar's advanced polymer conjugation technology to slow drug entry into the central nervous system (CNS). By dramatically slowing the rate of drug entry into the CNS, NKTR-192 is intended to maintain opioid-like efficacy without the abuse potential associated with rapid-acting opioids.
Cimzia®
Nektar technology is used in the antibody fragment, Cimzia® (certolizumab pegol). Cimzia is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA for Crohn's disease. This product is approved in the U.S. and filed in the EU for rheumatoid arthritis and in phase 3 for ankylosing spondylitis and psoriatic arthritis. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales for all indications.
NKTR-125
Combines Nektar Advanced Polymer Conjugate Technology™ with a potent antihistamine to enhance its anti-inflammatory properties and minimize the undesirable side effects.
Etirinotecan pegol (NKTR-102)
Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
Etirinotecan pegol (NKTR-102)
Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
Etirinotecan pegol (NKTR-102)
Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
Etirinotecan pegol (NKTR-102)
Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
OMONTYS® (peginesatide)
Nektar's proprietary conjugation technology is used in the novel peptide mimetic, OMONTYS (peginesatide) Injection. The therapeutic is a synthetic, peptide-based erythropoiesis-stimulating agent developed by Takeda and Affymax. Under the terms of an exclusive agreement between Nektar and Affymax, Nektar is entitled to receive royalties on the global sales of OMONTYS for all indications, as well as manufacturing revenues. OMONTYS is approved by the U.S. Food and Drug Administration (FDA)for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. A Marketing Authorization Application for peginesatide is currently under review by the European Medicines Agency.
CDP791
Nektar technology is used in the antibody fragment, CDP791. The product is in Phase 2 clinical trials for non-small cell lung cancer. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of CDP791 for all indications.
NKTR-228
NKTR-228 is a drug candidate designed to reduce parathyroid hormone levels in late stage renal disease patients. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
NKTR-214
NKTR-214 is a drug candidate designed to kill tumors through stimulation of the immune system. The product was developed using Nektar's advanced polymer conjugate technology and is in early research. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide | Copyright Nektar © 2012 |